Advances in the Treatment of Intermediate and Posterior Uveitis

Samantha Fraser-Bell; Carlos Pavesio


Expert Rev Ophthalmol. 2008;3(4):449-456. 

In This Article

Expert Commentary

The current strategy for the management of noninfectious posterior uveitis involves either local or systemic options. Local therapy has been predominantly delivered as periocular injections of steroids, but more recently intraocular steroids have gained popularity. Injections have a short-lived effect and repeating the procedure is necessary, increasing the risk of local complications. Slow-release devices offer a prolonged protection, but are not free of problems at local level. Systemic therapy with steroids and other immunosuppressive agents is a sensible alternative in bilateral disease, especially for those cases associated with a systemic disease. Clearly this approach carries the risk of systemic side effects and loss of control with relapses is not uncommon. New options have also become available in the form of monoclonal antibodies, which are proving very useful in resistant cases. Most of the experience to date has been with infliximab, but other alternatives such as adalimumab are showing good promise.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: